Q1 2025 saw 7% sales growth and a 17% EBITA margin, with strong performance in Assistive Tech and MedTech, but a sharp EBITA decline in Specialty Pharma due to lost royalties and weaker demand. M&A outlook remains positive, and net debt/EBITDA is -0.6.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.